Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel for the prevention of heartworm disease in cats

Special Issue – NexGard^® Combo (esafoxolaner, eprinomectin, praziquantel): A new endectocide spot-on formulation for cats. Invited Editor: Frédéric Beugnet

Open Access

Table 2

Heartworm count per treatment group and efficacy of NexGard^® Combo against D. immitis in cats.

	Treatment groups^a	n	Total D. immitis counts in individual cats at necropsy^b	D. immitis counts geometric mean	Efficacy	P-value	Total live D. immitis counts by sex/Total live count ranges per cat by sex
Study 1	Control (Placebo)	10	0, 1, 2, 5, 8, 8, 8, 14, 16, 16	5.1	NA	NA	32 m & 43 f/2–9 m & 1–11 f
Study 1	NexGard^® Combo	10	0 in each of the 10 cats	0.0	100%	<0.0001	0/0
Study 2	Control (Placebo)	10	0, 0, 0, 1, 1, 1, 3, 6, 6, 7	1.6	NA	NA	15 m & 10 f/1–4 m & 1–4 f
Study 2	NexGard^® Combo	10	0 in each of the 10 cats	0.0	100%	0.0024	0/0

m = male; f = female; NA = not applicable.

Placebo group treated once on Day 0 with 0.12 mL/kg of mineral oil and NexGard^® Combo Group treated once on Day 0 with 0.12 mL/kg of the novel formulation delivering 1.44 mg/kg esafoxolaner, 0.48 mg/kg eprinomectin, and 10.0 mg/kg praziquantel.

All D. immitis were alive, except in two cats in Study 1 having one or 2 dead fragmented D. immitis out of 8 and 16, respectively.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.